Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...
Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force behind its strong numbers. It may not be long before Novo Nordisk also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback